

FIRST GOVERNMENT RHINOSWAB ORDERS FOR LARGE SCALE SARS-CoV-2 TESTING

11 August 2021: Melbourne, Australia. Rhinomed Limited (ASX:RNO OTCQB:RHNMF), a leader in wearable nasal and respiratory technology, has received purchase orders and begun supplying NSW Health Pathology with an initial one million Rhinoswabs as part of their program to support testing capability.

The company has commenced deliveries with these initial orders being fulfilled over coming weeks. Rhinomed is now scaling up its manufacturing facilities to respond to growing domestic and international demand for this innovative technology.

Rhinomed's Rhinoswab technology improves the sample collection process. As previously disclosed the Rhinoswab is substantially more comfortable and easier to use than the standard nasal swab, captures a larger sample, can accelerate the sample collection process and significantly reduce queues and waiting times. Rhinoswab works with existing PCR pathology workflows and equipment and has equivalent cost and quality to the US and European standard of care nasopharyngeal swabs.

Rhinomed has leveraged its deep expertise in wearable nasal medical devices to develop a novel nasal swab that is easier, and more comfortable to use. Interim results from a recent comparison study (n= 204) being completed at CWZ and Radboud University Medical Center, a leading teaching hospital in Nijmegen in the Netherlands are in line with the previously announced user study results and showed participants' strong preference for the Rhinoswab when compared to the traditional nasal swab:

- 89% of respondents preferred Rhinoswab to the Nasopharyngeal swab
- 98% of respondents felt no pain with Rhinoswab vs 48% with Nasopharyngeal swab
- 98% of respondents needed little or no guidance when using Rhinoswab™

Rhinomed CEO Michael Johnson said, "We are thrilled to receive this support for this Australian innovation. The Rhinoswab can make a meaningful impact on the SARS-CoV-2 testing process and enable more people to be tested quickly and easily. With approximately 2 billion SARS-CoV-2 tests having been carried out globally over the last 18 months (close to 26 million* in Australia alone), there is a major opportunity for Rhinoswab to radically improve the testing process, clinical outcomes and user experience."

The Rhinoswab is registered with the US FDA, Australian TGA and has a European CE mark. The company is developing an increasing sales pipeline and will update investors as these agreements occur. The revenue associated with the initial order represents between approximately 25% and 35% of unaudited FY21 revenues of \$3.9m. The details of the order are commercial in confidence. This announcement discloses all of the material details as required under section 4.15 of Guidance Note 8. For further information about Rhinoswab visit <https://www.rhinomed.global/about-rhino-med/sample-collection/>

This announcement has been authorised for release to the market by the Board.

Company	Investor and Media Relations
Michael Johnson, CEO & Director +61 (0) 3 8416 0900 mjohnson@rhinomed.global	Rudi Michelson Monsoon Communications +61(0) 411 402 737 rudim@monsoon.com.au

About Rhinomed Limited (ASX: RNO, OTCQB:RHNMF)

Rhinomed Limited is a Melbourne, Australia based ASX listed medical device company that has developed a novel wearable nasal technology platform that can improve air flow and provide both drug delivery and diagnostic capabilities.

* <https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert/coronavirus-covid-19-case-numbers-and-statistics>